Steroid treatment within seven () days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to  mg Prednisolone PO QD (or equivalent), daily (or less) at least seven () days prior to study drug administration are allowed. Phase  Tumor-specific Eligibility Criteria Phase  patients must meet the cohort-specific inclusion/exclusion criteria in addition to the general inclusion/exclusion criteria for Phase  and Phase  study listed above. Cohort : Patient Population: Relapsed/Refractory SCLC
COHORT A SPECIFIC ELIGIBILITY CRITERIA:
COHORT B SPECIFIC ELIGIBILITY CRITERIA:
PROTOCOL-SPECIFIC CRITERIA:
PROTOCOL-SPECIFIC CRITERIA:
PHASE  SPECIFIC ELIGIBILITY CRITERIA
PHASE  SPECIFIC ELIGIBILITY CRITERIA
PHASE  SPECIFIC EXCLUSION CRITERIA
For Phase A: no specific restriction
SPECIFIC INCLUSION CRITERIA FOR PHASE II
Cohort-specific criteria for Phase :
A history or evidence of cardiovascular risk- specific criteria have to be met
Specific Eligibility Criteria, Part A
Specific Eligibility Criteria, Part B
Solid tumor cohort (B) specific criteria
Prior anti-cancer treatment permitted (with specific criteria)
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Agent specific limitations on prior therapy will be included with specific treatment subprotocols
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Additional agent specific criteria will be included with specific treatment subprotocols